

**Table 7. Antiretroviral Components Not Recommended as Initial Therapy (Updated January 29, 2008)**

| Antiretroviral drugs or components<br>(in alphabetical order)                                       | Reasons for not recommending as initial therapy   |
|---|---|
| Abacavir/lamivudine/zidovudine<br>(coformulated) as triple-NRTI combination<br>regimen <b>(DII)</b> | <ul style="list-style-type: none"> <li>• Inferior virologic efficacy</li> </ul>   |
| Darunavir (ritonavir-boosted) <b>(DIII)</b>   | <ul style="list-style-type: none"> <li>• Insufficient data in treatment-naïve patients</li> </ul>   |
| Delavirdine <b>(DII)</b>  | <ul style="list-style-type: none"> <li>• Inferior virologic efficacy</li> <li>• Inconvenient (three times daily) dosing</li> </ul>  |
| Didanosine + tenofovir <b>(DII)</b>   | <ul style="list-style-type: none"> <li>• High rate of early virologic failure</li> <li>• Rapid selection of resistant mutations</li> <li>• Potential for immunologic non-response/CD4 decline</li> </ul>                                      |
| Enfuvirtide <b>(DIII as initial regimen)</b>  | <ul style="list-style-type: none"> <li>• No clinical trial experience in treatment-naïve patients</li> <li>• Requires twice-daily subcutaneous injections</li> </ul>  |
| Etravirine <b>(DIII)</b>  | <ul style="list-style-type: none"> <li>• Insufficient data in treatment-naïve patients</li> </ul>   |
| Indinavir (unboosted) <b>(DIII)</b>   | <ul style="list-style-type: none"> <li>• Inconvenient dosing (three times daily with meal restrictions)</li> <li>• Fluid requirement</li> </ul>   |
| Indinavir (ritonavir-boosted) <b>(DII)</b>  | <ul style="list-style-type: none"> <li>• High incidence of nephrolithiasis</li> </ul>   |
| Maraviroc <b>(DIII)</b>   | <ul style="list-style-type: none"> <li>• Insufficient data in treatment-naïve patients</li> </ul>   |
| Nelfinavir <b>(DII)</b>   | <ul style="list-style-type: none"> <li>• Inferior virologic efficacy</li> </ul>   |
| Raltegravir <b>(DIII)</b>   | <ul style="list-style-type: none"> <li>• Insufficient data in treatment-naïve patients</li> </ul>   |
| Ritonavir as sole PI <b>(DIII)</b>  | <ul style="list-style-type: none"> <li>• High pill burden</li> <li>• Gastrointestinal intolerance</li> </ul>  |
| Saquinavir (unboosted) <b>(DII)</b>   | <ul style="list-style-type: none"> <li>• High pill burden</li> <li>• Inferior virologic efficacy</li> </ul>   |
| Stavudine + lamivudine <b>(DI)</b>  | <ul style="list-style-type: none"> <li>• Significant toxicities including lipoatrophy, peripheral neuropathy, and hyperlactatemia, including symptomatic and life-threatening lactic acidosis, hepatic steatosis, and pancreatitis</li> </ul> |
| Tipranavir (ritonavir-boosted) <b>(DII)</b>   | <ul style="list-style-type: none"> <li>• Inferior virologic efficacy</li> </ul>   |